title: Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.
abstract: BACKGROUND
  XR5000 is a tricyclic carboxamide that intercalates DNA and inhibits both topoisomerase I and II. The aim of this study was to evaluate the efficacy and tolerability of XR5000 in patients with recurrent glioblastoma multiforme previously untreated with chemotherapy at relapse.
  
  
  METHODS
  Patients received XR5000 at a dose of 3010 mg/m2 as a 120-h central venous infusion every 3 weeks. An independent panel assessed response every two cycles using McDonald's criteria (tumour size, steroid intake and neurological status); toxicity was graded according to the National Cancer Institute-Common Toxicity Criteria, version 2.0.
  
  
  RESULTS
  Sixteen patients were enrolled (one ineligible patient was excluded from efficacy evaluation). Performance status was zero (five patients), one (nine patients) or two (one patient). They received 30 cycles of XR5000 (median 2, range 1-5). Haematological toxicity was mild, with only one patient experiencing grade 3 neutropenia. Other related grade 3/4 adverse events included chest pain (one patient), axillary vein thrombosis (one patient) and rigors/fever in the absence of neutropenia (one patient). There were no objective responses, 14 patients progressing on XR5000 and one having stable disease.
  
  
  CONCLUSIONS
  Although XR5000 was generally well tolerated, these results do not support further evaluation in patients with glioblastoma multiforme using this dose and schedule.
authors.affiliation: Cancer Research UK, Department of Medical Oncology and Beatson Oncology Centre, Glasgow. c.twelves@beatson.gla.ac.uk
authors.forename: C
authors.initials: C
authors.lastname: Twelves
authors.forename: M
authors.initials: M
authors.lastname: Campone
authors.forename: B
authors.initials: B
authors.lastname: Coudert
authors.forename: M
authors.initials: M
authors.lastname: Van den Bent
authors.forename: M
authors.initials: M
authors.lastname: de Jonge
authors.forename: C
authors.initials: C
authors.lastname: Dittrich
authors.forename: R
authors.initials: R
authors.lastname: Rampling
authors.forename: R
authors.initials: R
authors.lastname: Sorio
authors.forename: D
authors.initials: D
authors.lastname: Lacombe
authors.forename: C
authors.initials: C
authors.lastname: de Balincourt
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
mesh_terms: D000166:Acridines / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000166:Acridines; C121181:DACA, acridine